Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor

Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor

Background and Purpose: Angiotensin receptor-NEP inhibitor (ARNi), which includes an angiotensin receptor blocker (ARB) and a neprilysin inhibitor (NEPi), has been proven safe and effective for treating heart failure with reduced ejection fraction (HF-REF). S086 is a novel single-molecule ARNi that...

Full description

Bibliographic Details
Main Authors:	Jingchao Sun, Wenjie Xu, Huaijie Hua, Ying Xiao, Xiaoyan Chen, Zhiwei Gao, Song Li, Xiaolong Jing, Frank Du, Guofeng Sun
Format:	Article
Language:	English
Published:	Elsevier 2020-09-01
Series:	Biomedicine & Pharmacotherapy
Subjects:	Angiotensin receptor-NEP inhibitor Heart failure Neprilysin inhibitor Angiotensin receptor blocker
Online Access:	http://www.sciencedirect.com/science/article/pii/S075333222030603X

Similar Items

Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence
by: Hong-Mi Choi, et al.
Published: (2020-05-01)

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
by: Sarah L Anderson, et al.
Published: (2018-08-01)

Long-Term Effects of Angiotensin Receptor–Neprilysin Inhibitors on Myocardial Function in Chronic Heart Failure Patients with Reduced Ejection Fraction
by: Gregor Poglajen, et al.
Published: (2020-07-01)

Reply to Siniorakis et al., “COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure”
by: David S. Fedson, et al.
Published: (2020-05-01)

Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats
by: Shao-Jung Hsu, et al.
Published: (2020-04-01)

Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis
by: Wipharak Rattanavipanon, et al.
Published: (2021-07-01)

Effect of angiotensin receptor neprilysin inhibitor on ventricular remodeling after myocardial infarction in rats
by: Jian An
Published: (2020-11-01)

Angiotensin receptor neprilysin inhibitor in inotrope dependent heart failure patients: A case series
by: Sepideh Taghavi, et al.
Published: (2020-12-01)

Outcome of angiotensin receptor-neprilysin inhibitor on anxiety and depression in heart failure with reduced ejection fraction vs. heart failure with preserved ejection fraction
by: Jahanzeb Malik, et al.
Published: (2021-09-01)

Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure
by: Kawa Dizaye, et al.
Published: (2019-05-01)

A clinical experience of Indian patients with heart failure with reduced left ventricular ejection fraction using an angiotensin receptor-neprilysin inhibitor [ARNI] on an outpatient basis
by: Pankaj Jariwala, et al.
Published: (2021-03-01)

ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS: IS THERE A REASON TO CONSIDER AN EQUIVALENCE OF TWO DRUG CLASSES FROM THE EVIDENCE BASED MEDICINE STANDPOINT
by: S. Yu. Martsevich
Published: (2015-09-01)

Hyponatremia Induced by Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers-A Pilot Study
by: S Bhuvaneshwari, et al.
Published: (2018-07-01)

Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease
by: Yudi Her Oktaviono, et al.
Published: (2020-04-01)

Relating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID‐19
by: Martin C.S. Wong, et al.
Published: (2020-10-01)

TO THE 110-TH ANNIVERSARY OF RENIN FINDING. FIGHT OF TITANS: ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND SARTANS
by: L. N. Malay, et al.
Published: (2016-01-01)

Angiotensins and rheumatoid arthritis
by: N. M. Savushkina, et al.
Published: (2019-01-01)

COVID-19 morbidity and mortality associated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use among 14,129 patients with hypertension from a US integrated healthcare system
by: Jaejin An, et al.
Published: (2021-06-01)

Angiotensin-converting enzyme inhibitors or sartans in patients at high risk for cardiovascular events: a wrong question or an undesirable answer
by: S R Gilyarevsky, et al.
Published: (2013-03-01)

Angiotensin receptor blocker-induced bilateral ciliochoroidal effusion
by: Kanika Aggarwal, et al.
Published: (2020-01-01)

Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study
by: Melissa Y. Y. Moey, et al.
Published: (2019-07-01)

The effects of adding angiotensin receptor neprilysin inhibitors to usual care in patients with heart failure: a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis
by: Emil Eik Nielsen, et al.
Published: (2019-10-01)

Group-Based Trajectory Modeling to Identify Patterns of Adherence and Its Predictors Among Older Adults on Angiotensin-Converting Enzyme Inhibitors (ACEIs)/Angiotensin Receptor Blockers (ARBs)
by: Paranjpe R, et al.
Published: (2020-10-01)

The immuneregulator role of neprilysin (NEP) in invertebrates
by: E Ottaviani, et al.
Published: (2012-11-01)

The immuneregulator role of neprilysin (NEP) in invertebrates
by: E Ottaviani, et al.
Published: (2012-11-01)

Resistance to antihypertensive drugs targeting Renin-Angiotensin-Aldosterone-System in cancer patients: a case series
by: Mishita Goel, et al.
Published: (2020-08-01)

Blocking angiotensin earlier with RAS blockers, statins, and heparin in high-risk COVID-19 patients: Is the remedy here?
by: Imdat Eroğlu, et al.
Published: (2020-07-01)

Prescriptions for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and monitoring of serum creatinine and potassium in patients with chronic kidney disease
by: Pei-Tzu Wang, et al.
Published: (2012-09-01)

Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study
by: Francisco J. de Abajo, et al.
Published: (2021-05-01)

Angiotensin II Receptor Blockers but Not Angiotensin-Converting Enzyme Inhibitors Are Associated With a Reduced Risk of Acute Kidney Injury After Major Surgery
by: Shao-Yu Yang, et al.
Published: (2021-04-01)

A systematic review of the blood pressure lowering efficacy of ACE inhibitors and angiotensin receptor blockers for primary hypertension
by: Heran, Balraj Singh
Published: (2008)

A systematic review of the blood pressure lowering efficacy of ACE inhibitors and angiotensin receptor blockers for primary hypertension
by: Heran, Balraj Singh
Published: (2008)

A systematic review of the blood pressure lowering efficacy of ACE inhibitors and angiotensin receptor blockers for primary hypertension
by: Heran, Balraj Singh
Published: (2008)

ACE inhibitor angioedema: characterization and treatment versus non-ACE angioedema in acute hospitalized patients
by: David S. Weisman, et al.
Published: (2020-01-01)

Angiotensin receptor blockers in heart failure after the ELITE II trial
by: Willenheimer Ronnie
Published: (2000-09-01)

Perspectives of using angiotensin receptor antagonists
by: V V Fomin
Published: (2009-06-01)

Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias
by: Henry Sutanto, et al.
Published: (2021-08-01)

The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer’s disease: the importance of blood-brain barrier penetration and APOE ε4 carrier status
by: Michael Ouk, et al.
Published: (2021-02-01)

Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Acute Kidney Injury in Emergency Medical Admissions
by: Athanasios Feidakis, et al.
Published: (2021-01-01)

Effects of Angiotensin II Type 1A Receptor on ACE2, Neprilysin and KIM-1 in Two Kidney One Clip (2K1C) Model of Renovascular Hypertension
by: Laale F. Alawi, et al.
Published: (2021-01-01)

Cannot write session to /tmp/vufind_sessions/sess_cec7tuvnmct0r57r5fghg6t2o7